Interleukin-10 (IL-10) has an important role in the homeostatic regulation of autoreactive T-cell repertoire. We hypothesized that endogenous IL-10 would regulate the severity of b-tubulin-induced experimental autoimmune hearing loss (EAHL) and that exogenous IL-10 would abrogate it. BALB/c wild-type (WT) and homozygous IL-10-deficient mice (IL-10 À/À ) underwent b-tubulin immunization to develop EAHL; some IL-10 mice with EAHL were administered IL-10 DNA at the peak of EAHL. Auditory brainstem responses were examined over time. EAHL developed progressively in both WT and IL-10 À/À mice. However, the severity of hearing loss in the IL-10 À/À mice was significantly greater than that in WT animals. Moreover, disease severity was associated with a significantly enhanced interferon-g level and loss of hair cells in IL-10 À/À mice. IL-10 administered to EAHL IL-10 À/À mice promoted IL-10 expression. Consequently, hearing significantly improved by protecting hair cells in established EAHL. Importantly, IL-10 treatment suppressed proliferation of antigen-specific T-helper type 1 (Th1) cells, and the suppression can be attributed to inducing IL-10-secreting regulatory T cells that suppressed autoreactive T cells. We demonstrated that the lack of IL-10 exacerbated hearing loss, and the exogenous administration of IL-10 improved hearing. Mechanistically, our results indicate that IL-10 is capable of controlling autoimmune reaction severity by suppressing Th1-type proinflammatory responses and inducing IL-10-secreting regulatory T cells.
INTRODUCTION
Autoimmune inner ear disease (AIED) was first described by McCabe in 1979. 1 He described patients with progressive, bilateral, synchronous or sequential, sensorineural hearing loss who responded to immunosuppressive therapy and who also tested positive for laboratory tests, clinical manifestations and immunological tests prescribed for autoimmune hearing loss. 2 Baek et al. 3 demonstrated that patients with AIED have higher frequencies of interferon (IFN)-g-producing T cells and higher serum antibody titers compared with both normal hearing control subjects and patients with noise-and/or age-related hearing loss. Many autoantigens have been implicated as possible causal antigens (Ags) in AIED: heat-shock protein 70, 4, 5 collagen II, 6 cochlin 3, 7 and, most recently, b-tubulin. [8] [9] [10] [11] [12] [13] Yoo et al. [9] [10] [11] demonstrated that 67 (59%) of 113 patients with Ménière's disease had antibodies to a 55-kDa protein b-tubulin in guinea-pig inner ear extract. Moreover, immunohistological studies showed that b-tubulin appeared to be a highly expressed protein in inner ear tissues such as hair cells, supporting cells, spiral ligament of stria vascularis, neural pathway of the cochlea, as well as spiral ganglion, indicating that b-tubulin is a fundamental protein in guinea-pig inner ear. 9, 12 Nevertheless, inner ear immunization with b-tubulin changed b-tubulin spatial distribution in specific structures 12 and caused degeneration of the spiral ganglion, 12 thereby affecting the function of microtubules in the stria vascularis and spiral ganglion. More recently, Zhou et al. 8 and Cai et al. 13 developed a form of experimental autoimmune hearing loss (EAHL) by immunizing BALB/c mice with recombinant b-tubulin. These mice developed substantial hearing loss associated with degeneration of the organ of Corti and spiral ganglion cells, and this type of EAHL could be passively transferred into naïve recipient mice by CD4 + T cells. 8 Moreover, these mice showed robust proliferative responses and increased production of IFN-g when stimulated in vitro with b-tubulin. 8 Subsequent studies by Cai et al. 13 showed that peripheral tolerance could be induced by oral administration of low-dose b-tubulin peptide in an animal model of AIED. 13 This treatment showed less hearing loss and less inner ear damage and decreased IFN-g secretion in response to b-tubulin and demonstrated an effective, Ag-specific method to suppress EAHL.
Although the actual triggers leading to AIED are unclear, in vitro proliferation of T cells and frequency of IFN-g secretion from AIED patients in response to human inner ear homogenate indicate an autoantigen-driven T-cell expansion in AIED. 7, 8, 14, 15 Transfer studies indicate that Ag-specific CD4 + T cells with a T-helper type 1 (Th1)-like phenotype mediate the development of EAHL by showing significantly increased auditory brain stem thresholds after adoptive transfer of autoantigen-activated CD4 + T cells into naïve recipients. 7, 8, 16, 17 Recently, accumulating evidence has suggested that regulatory T (Treg) cells have a critical role in maintaining peripheral homeostasis and establishing controlled immune responses. [18] [19] [20] There are two classes of Treg cells within CD4 + T cells: (1) the naturally occurring, thymus-selected CD4 + CD25 + Foxp3 + Treg cells, 19 which develop in the thymus and are present in normal naïve mice and healthy individuals from birth; and (2) the inducible Treg cells including Tr1 and Th3 cells, which are generated in the periphery under various tolerogenic conditions. 21, 22 Naturally occurring Treg cells constitutively express both CD25 (refs 23,24) and Foxp3, 25 and Foxp3 has a crucial role in developing and maintaining Treg cells. Foxp3 mutations result in the loss of Treg cells and underlie a homologous autoimmune lymphoproliferative disorder. [26] [27] [28] [29] Interleukin-10 (IL-10) is a potent immunomodulatory cytokine in the homeostatic regulation of the autoreactive T-cell repertoire. 30 The anti-inflammatory properties involve suppressing both Th1 and Th2 cytokine responses, thereby inducing anergy or tolerance when applied to CD4 + or dendritic cells. 31, 32 Moreover, IL-10 depletion and IL-10 treatment in murine arthritis models 33, 34 have demonstrated the antiinflammatory properties of IL-10 in arthritis. Furthermore, IL-10 can inhibit the production of proinflammatory chemokines and cytokines in activated monocytes/macrophages and suppress the proliferation of CD4 + T cells by downregulating the Ag-presenting cell (APC) function. 35 In addition, IL-10 promotes the generation of IL-10-secreting Treg cells that suppress Ag-specific T-cell responses and prevent colitis. 21, 36 Therefore, exploiting immuno regulatory cytokine IL-10 to propagate anti-autoimmune responses can be a promising approach for treating autoimmune disorders.
To investigate the efficacy of complete elimination of IL-10 in vivo on the development of b-tubulin-induced EAHL and to understand the mechanism responsible for IL-10 regulation, we evaluated the development of EAHL in homozygous IL-10-deficient mice. In addition, we hypothesized that administering vectors encoding murine IL-10 would prove efficacious in treating EAHL in IL-10 À/À mice. In this article, we demonstrate that the lack of IL-10 exacerbates hearing loss, and the exogenous administration of IL-10 improves hearing function.
RESULTS
Lack of biologically active IL-10 exacerbates hearing loss in IL-10 À/À mice with EAHL To examine whether IL-10 functions as an endogenous inhibitor of autoimmune diseases, we evaluated the development of disease by using the EAHL model. Wild-type (WT) and IL-10 À/À BALB/c mice, which showed normal auditory brainstem response (ABR) behavior before immunization, were immunized with b-tubulin subcutaneously. All b-tubulin-immunized-IL-10 À/À mice succumbed to a significant increase in ABR thresholds in comparison with b-tubulin-immunized WT mice. Tests involved click (P¼0.0005) and puretone thresholds at 8, 16 and 32 kHz (P¼0.001, 0.004 and 0.0005, respectively), but the onset of disease was delayed for a few weeks in WT mice compared with IL-10 À/À mice (Figures 1a-d) , such as 4 weeks for 32 kHz, 3 weeks for click and 2 weeks for 8 and 16 kHz. Interestingly, the ABR thresholds of hearing loss at all frequencies tested in WT animals began to recede 6À7 weeks after b-tubulin immunization, and the ABRs detected threshold levels similar to those in naïve mice that received no immunization 11 weeks after b-tubulin immunization (Figures 1a-d) . However, all IL-10 À/À mice remained with hearing loss, even at the time the experiments were terminated. Hearing loss in IL-10 À/À mice was markedly exacerbated in comparison with WT mice (Figures 1a-d) ; after 2 weeks of b-tubulin immunization, IL-10 À/À mice had a significant increase in ABR click, 8 and 16 kHz thresholds. Only 1 week after immunization, IL-10 À/À mice showed significantly elevated ABR thresholds at 32 kHz compared with WT mice. All enhancements in ABR threshold remained until the experiments were terminated. Taken together, these results demonstrate that endogenous IL-10 may regulate proinflammatory mediators in vivo and is important for controlling disease severity. Exogenous administration of IL-10 ameliorates established EAHL To examine whether exogenous administration of IL-10 is sufficient to ameliorate established EAHL, IL-10-deficient mice were intramuscularly injected with plasmid DNA encoding IL-10 at weeks 3 and 4 after b-tubulin immunization. ABR thresholds for b-tubulin-immunized IL-10 À/À mice were measured over time (Figure 3 ). At 1 week after IL-10 gene transfer (Figure 3a) , the IL-10 DNA administration group showed that the ABR threshold to click stimulus and a wide range of specific frequencies significantly decreased in comparison with the control DNA group. Mean intensity threshold of click in the IL-10 DNA administration group had a marked improvement in hearing compared with the control DNA group; the threshold level of click was very similar in the naïve mice as well (Figure 3a) . At 5 weeks after IL-10 gene transfer (Figure 3b ), ABR click and pure-tone thresholds of the IL-10 DNA administration group showed improvement in hearing level at all frequencies tested from 8 to 32 kHz. ABR tests detected similar threshold levels in naïve mice ( Figure 3b ) and completely restored hearing in IL-10-treated mice, whereas the control DNA group developed EAHL. Therefore, electrophysiology tests demonstrated recovery of hearing to click stimulus and a wide range of specific frequencies 5 weeks after IL-10 gene transfer. 37, 38 In this study, our overall aim was to define the role of both endogenous and exogenous IL-10 in the setting of b-tubulin-induced EAHL. In our study, EAHL developed progressively in b-tubulin-immunized IL-10 À/À mice throughout the experiment, and the hearing loss lasted at least 9 weeks after immunization. Moreover, hair cell loss and degeneration of spiral ganglion cells in the basal turn of cochleae were observed in IL-10 À/À mice with EAHL. However, IL-10 administration to IL-10 À/À mice at the peak of EAHL (3 and 4 weeks after immunization) significantly improved hearing function. At 5 weeks after injections, the ABR thresholds in the IL-10 DNA exposure group were equivalent to naïve controls, and histological analysis of cochlear cross-sections was similar to those of naïve mice. The anti-inflammatory properties of IL-10 suggest that endogenous IL-10 may regulate proinflammatory mediators in vivo. 39, 40 Comparison of auditory function and cochlear histology between WT and IL-10 À/À mice suggests that the achieved results critically depend on the timing of IL-10 overexpression. In Figure 1 shows that WT mice developed functional impairment of hearing at a reproducible point in time (approximately week 4 to 5) after the primary b-tubulin immunization. A few weeks later, auditory function improved spontaneously and basically returned to the level of normal hearing mice. On the cellular level at this point, histology showed degeneration of the spiral ganglion cells, but hardly any hair cell loss. Thus, there is a certain disparity between the cellular changes (neuronal degeneration) and the functional changes that are induced by the immunization with b-tubulin (spontaneous improvement of hearing between weeks 8 and 9 after the primary immunization). In contrast, in the IL-10 À/À mice, functional hearing loss commenced earlier and was more severe and non-remitting. This marked functional difference in comparison with the WT mice was paralleled by a marked difference at the cellular level, that is, the even more pronounced neuronal degeneration in the spiral ganglion and the marked loss of hair cells. This finding suggests that the extensive and long-lasting hearing loss in the IL-10 À/À mice is primarily the result of hair cell loss, at least after a certain point in time. This assumption is supported by the fact that genetic overexpression of IL-10 in IL-10 À/À mice resulted in restoration of auditory function and a normal histology at week 12. This finding suggests that the plasmid-encoded IL-10 was administered just in time to prevent hair cell loss, because a full regeneration of the lost hair cells seems highly unlikely. On the basis of these considerations, one could conclude that plasmid transfer at a later point in time, for example, weeks 8 and 9, would not achieve the same functional result because of established loss of hair cells and severe neuronal damage, whereas the plasmid administration at weeks 6 and 7, as used in this study, takes effect early enough to prevent that from happening.
IL-10 DNA administration protects hair cells in established EAHL
In our experiments, the release of IFN-g from cultured spleen cells isolated from IL-10 À/À mice with EAHL was significantly increased. In IL-10 À/À mice, persistent uncontrolled release of IFN-g may have led to excessive production and uncontrolled activation of the Th1 T cells reactive to Ag, thus converting the protective response to a pathological reaction. However, IL-10 DNA administration suppressed We demonstrated persistent IL-10 expression for at least 5 weeks in splenocyte cultures harvested from IL-10 À/À mice with EAHL after IL-10 DNA injections. Thus, it is possible to assess the sequelae of IL-10 DNA administration for at least 5 weeks after injections. IL-10 is a major cytokine for Treg cells and has an important role in controlling autoimmunity and inducing peripheral tolerance in vivo. 20, 41, 42 The production of IL-10 by splenocytes suggests the possibility that IL-10 DNA administration may induce IL-10-producing Treg cells that suppress the effector responses.
We therefore examined the possibility that this suppression is mediated through the production of Treg cells in vivo. We found a significantly elevated number of CD4 + CD25 + Foxp3 + cells in the spleen of the IL-10 DNA-administered group compared with the control group. Also, CD4 + CD25 + cells isolated from the IL-10 DNAadministered group showed profound immunosuppressive activities on b-tubulin-specific effector T cells. These effects were significantly abrogated by anti-IL-10 antibodies. Therefore, IL-10 DNA administration could induce IL-10-producing Treg cells that suppress effector T cells against autoantigen in IL-10 À/À mice with EAHL. IL-10 appears to be critical in mediating T-cell tolerance and protecting against autoantigen-induced EAHL. Moreover, IL-10 has systemic anti-inflammatory properties, suppressing both Th1 and Th2 cytokine responses; therefore, it induces anergy or tolerance when applied to CD4 + or dendritic cells. 31, 32 The presence of IL-10-producing CD4 + CD25 + Foxp3 + Treg cells might explain how IL-10 is able to reverse established EAHL in IL-10 À/À mice.
In summary, these results suggest that a lack of IL-10 exacerbates hearing loss, and exogenous administration of IL-10 improves hearing function, all of which indicates that IL-10 is an important regulator of inflammation in vivo. Moreover, our data demonstrate that the efficacy of IL-10 administration could result from immunosuppression due to long-term secretion of IL-10. Alternatively, IL-10 exposure may result in the differentiation of IL-10-producing CD4 + CD25 + Foxp3 + Treg cells. Therefore, IL-10 may restore immunological homeostasis by suppressing the autoimmune responses and generating the regulatory endogenous IL-10 response.
MATERIALS AND METHODS Mice
Female BALB/c mice (WT) and IL-10 knockout BALB/c mice (IL-10 À/À ) (Jackson Laboratory, Bar Harbor, ME, USA) were used in this study, and ABRs were measured bilaterally, both pre-and post-treatment, for all the mice to ensure their normal hearing function. Mice were maintained in the animal facility at the University of Tennessee Health Science Center, according to the institutional guidelines for animal care and use. These studies were approved by the Institutional Animal Care and Use Committee of the University of Tennessee. 
Hearing tests
During ABR measurements, mice were anesthetized with Avertin (500 mg kg À1 body weight). Farfield auditory brainstem-evoked response was conducted in a sound-attenuating booth. ABRs were recorded between subcutaneous needle electrodes in the vertex as active, posterior bulla as reference and ground electrode placed at the lower back. Click and tone burst stimuli of 8, 16 and 32 kHz were generated and delivered to both ears through a high-frequency transducer. A maximum sound pressure level was stimulated in tone bursts of 100 dB. The evoked potentials were amplified 5000 times and averaged from 600 evoked responses for the first 10-ms period following stimulation. Auditory thresholds were determined by increasing the sound intensity of the tone burst for each frequency stimulus and verified twice. Auditory-evoked potential amplitude was calculated from all traces between the maximum intensity of 100 dB, and the minimum intensity as hearing threshold was determined.
In vitro cytokine production and lymphocyte proliferation At 9 weeks after b-tubulin immunization, splenocytes from WT and IL-10 À/À mice were harvested. Cells (2Â10 5 cells per well) were cultured in 96-well flatbottomed plates (Costar, Corning, NY, USA) in RPMI 1640 medium supplemented with 5% fetal calf serum (Gibco, Paisley, UK), 50 mM 2-mercaptoethanol, 2 mM L-glutamine and 10 U penicillin/streptomycin (Gibco) and stimulated with b-tubulin in serial 10-fold dilutions. Positive control wells contained 2 mg ml À1 anti-mouse CD3 (BD Biosciences, San Diego, CA, USA), and negative control wells contained only phosphate-buffered saline. Supernatants were harvested after 48 h and stored at À70 1C for cytokine measurement. Cells were pulsed with 3 H-thymidine during the last 18 h of the 72-h assay, harvested and counted for 3 H-thymidine incorporation (Packard Instrument, Boston, MA, USA). Stored supernatants were analyzed for IL-4, IL-10, IFN-g and tumor growth factor-b by enzyme-linked immunosorbent assay, according to the manufacturer's protocol (R&D Systems, Minneapolis, MN, USA).
Flow cytometry
Flow cytometry was performed on freshly isolated spleen cells. The CD4 + CD25 + Foxp3 + -expressing T cells were identified by staining splenocytes with phycoerythrin-labeled anti-CD4 (RM4-5; eBioscience, San Diego, CA, USA) and APC-labeled anti-CD25 (PC61.5; eBioscience). For intracellular staining of Foxp3, cells were fixed and permeabilized according to the manufacturer's instructions before incubation with fluorescein isothiocyanate-labeled anti-mouse Foxp3 (FJK-16s; eBioscience). Appropriate isotypematched control antibodies were used to determine nonspecific staining. Labeled cells were washed with phosphate-buffered saline, and at least 10 000 cells were analyzed from each sample by flow cytometry with an LSR II (BD Biosciences). The percentage of Treg cells was determined after gating on CD4 + T cells and using the FlowJo software (Tree Star, Ashland, OR, USA).
In vitro suppression assay
Isolation of mouse CD4 + , CD4 + CD25 À and CD4 + CD25 + T cells was performed by using a mouse Treg isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Briefly, CD4 + T cells were first enriched by negative selection (depleting CD8a, CD11b-, CD45R-, CD49b-and Ter-119-positive cells) with magnetic activated cell separation. The CD4 + T cells were incubated with magnetic beads conjugated with an anti-CD25 monoclonal antibody to separate CD4 + CD25 À and CD4 + CD25 + T-cell subpopulations. The purity of the resulting T-cell subpopulations was higher than 95% by flow cytometry.
Proliferation assays were performed in triplicate by culturing CD4 + CD25 -cells (responder, 5Â10 4 from splenocytes of b-tubulin-immunized IL-10 À/À mice), CD4 + CD25 + T cells (suppressor, 5Â10 4 from splenocytes of b-tubulinimmunized IL-10 À/À mice treated with either IL-10 or control DNA and naïve BALB/c mice) in 96-well plates with irradiated APCs (5Â10 4 from splenocytes of normal BALB/c mice) for 72 h at 37 1C in complete medium. Cultures were stimulated by b-tubulin (100 mg ml À1 ), and some co-cultures were treated with anti-IL-10 antibodies (10 mg ml À1 ; BD Pharmingen, San Diego, CA, USA). After 3 days, 1 mCi per well 3 H-thymidine was added. Incorporation of 3 H-thymidine was assessed after 16 h of additional culturing.
Histology
After anesthesia with Avertin, animals were perfused through the heart with a solution of warm 0.1 M phosphate buffer, followed by a warm buffered 1.5% paraformaldehyde solution for 2 min. This was followed by a second fixative containing cold 4% paraformaldehyde for 25 min. The animals were decapitated, the brain and brainstem were exposed and the entire head with temporal bone was immersed in 10% neutral formaldehyde solution and stored overnight. Temporal bones were dissected out and post-fixed in fresh fixative at 4 1C overnight. After rinsing with phosphate-buffered saline, the tissues were decalcified in Tris buffer (pH 7.2) containing 10% EDTA at 4 1C for a week. Then, the temporal bones were dehydrated and embedded in paraffin. Groups of 12-mm-thick sections were collected using a microtome and mounted in serial order. All sections were mounted and stained with standard hematoxylin and eosin and examined for evidence of defect or degeneration. All sections were examined with a light microscope (Carl Zeiss Axioskop 2 plus HAL 100 with final enlargement Â400). Digital images of sections were obtained using a camera (Leica) linked to a Windows computer.
Statistical analysis
Data were analyzed using analysis of variance or Student's t-test to compare differences between the treatment groups.
